BUZZ - MoonLake shares surge as AbbVie's skin disease drug data eases market concerns around competition
路透社2026/10/22 16:26October 22 - ** Shares of MoonLake Immunotherapeutics (MLTX.O) rose 21.7% to $12.96
** The share price increase was driven by AbbVie (ABBV.N) releasing late-stage clinical trial data for its dermatology drug lutikizumab, which showed efficacy for patients with hidradenitis suppurativa (HS) (link) improved only 8% over the placebo group
** MoonLake is developing sonelokimab, a dual IL-17A/F inhibitor targeting the same chronic inflammatory skin condition
** Wedbush analyst Yun Zhong said AbbVie's data was "disappointing," affirming that sonelokimab could be the "superior treatment option," and noted that the share price surge reflects optimism that "potential competitive pressure has eased"
** Cantor analysts commented, “For MLTX, this is clearly a short-term positive, given the competitive threat from AbbVie’s drug may be diminished”
** Including the day's move, MLTX is down 1.6% year to date
(To aid non-native English speakers, Reuters has automated translation of its reports into several other languages. Automated translation may contain errors or lack needed context; Reuters does not guarantee accuracy of the translated text and supplies it for reader convenience only. Reuters accepts no responsibility for any damage or loss caused by use of the automated translation feature.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Bitcoin rebounds sharply from oversold levels, briefly surpassing $57,000

Masayoshi Son's Trillion-Dollar Gamble: Once Considered Acquiring SK Hynix
According to reports, Masayoshi Son once planned to acquire the South Korean memory chip giant SK Hynix for nearly 1 trillion US dollars and had approached Wall Street institutions to seek financing, but SoftBank has confirmed it is no longer actively pursuing the deal. The massive financing requirement and South Korean regulatory restrictions were major obstacles. This plan also highlights SoftBank’s further strategic intention to invest in AI storage chips.
"Sell-offs bring more sell-offs! Goldman Sachs predicts another large-scale sell-off in the U.S. stock market in the coming week."
Goldman Sachs stated that the bank’s “panic index” has risen to 9 out of 10, with systemic selling pressure continuing to spread. In the coming week, CTAs may sell up to $80.6 billion in US stocks, and even if the market remains flat, there is still $65.8 billion in sell orders waiting to be executed. The Anthropic IPO failed to boost market risk appetite, and concerns over AI investment returns continue to weigh on tech stock valuations.
Chun purchased 7,186 ETH worth $11.74 million
